Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose versus high-dose prophylactic enoxaparin in critically ill ICU medical patients at high risk of thromboprophylaxis failure
2025-524864-40-00Phase 3Authorised
- Sponsor
- Erasmus Hospital
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Erasmus Hospital. Primary endpoint: Primary net clinical outcome at Day 28. Planned start Oct 2026; status: authorised.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2025-524864-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524864-40-00.